From the Journals
FDA & Government News
Fibromyalgia Drugs Tested for Value
Investigators compare common fibromyalgia therapies.
A recent study found that duloxetine 120 mg outperformed amitriptyline in terms of quality-adjusted life-years (QALYs) for adults with moderate to severe fibromyalgia, according to a decision analytical model. This model utilized a Markov cohort state transition framework that analyzed costs and QALYs associated with duloxetine and other FDA-approved treatments. Duloxetine produced 10.40 QALYs at a slightly higher cost of $115,770 compared to amitriptyline's 9.99 QALYs and $115,145 cost. The study emphasizes evaluating societal costs in fibromyalgia treatment choices.
